- Home
- ORIC vs EYPT Comparison
ORIC vs EYPT Comparison
Compare ORIC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- EYPT
- Stock Information
- Founded
- ORIC 2014
- EYPT 1987
- Country
- ORIC United States
- EYPT United States
- Employees
- ORIC N/A
- EYPT N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- ORIC Health Care
- EYPT Industrials
- Exchange
- ORIC Nasdaq
- EYPT Nasdaq
- Market Cap
- ORIC 1.1B
- EYPT 967.4M
- IPO Year
- ORIC 2020
- EYPT 2005
- Fundamental
- Price
- ORIC $12.20
- EYPT $11.65
- Analyst Decision
- ORIC Strong Buy
- EYPT Strong Buy
- Analyst Count
- ORIC 8
- EYPT 5
- Target Price
- ORIC $17.86
- EYPT $29.60
- AVG Volume (30 Days)
- ORIC 1.1M
- EYPT 1.4M
- Earning Date
- ORIC 11-13-2025
- EYPT 11-05-2025
- Dividend Yield
- ORIC N/A
- EYPT N/A
- EPS Growth
- ORIC N/A
- EYPT N/A
- EPS
- ORIC N/A
- EYPT N/A
- Revenue
- ORIC N/A
- EYPT $42,339,000.00
- Revenue This Year
- ORIC N/A
- EYPT N/A
- Revenue Next Year
- ORIC N/A
- EYPT N/A
- P/E Ratio
- ORIC N/A
- EYPT N/A
- Revenue Growth
- ORIC N/A
- EYPT N/A
- 52 Week Low
- ORIC $3.90
- EYPT $3.91
- 52 Week High
- ORIC $14.93
- EYPT $14.91
- Technical
- Relative Strength Index (RSI)
- ORIC 46.07
- EYPT 46.77
- Support Level
- ORIC $12.02
- EYPT $10.28
- Resistance Level
- ORIC $13.04
- EYPT $12.22
- Average True Range (ATR)
- ORIC 0.75
- EYPT 0.93
- MACD
- ORIC -0.12
- EYPT 0.00
- Stochastic Oscillator
- ORIC 20.69
- EYPT 55.72
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.